News

Market Beat
marketbeat. com > instant-alerts > atricure-nasdaqatrc-rating-lowered-to-buy-at-wall-street-zen-2026-05-02

Atri Cure (NASDAQ: ATRC) Rating Lowered to "Buy" at Wall Street Zen

3+ hour, 54+ min ago  (105+ words) Atri Cure (NASDAQ: ATRC - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday. Read Our Latest Stock Analysis on ATRC…...

Market Beat
marketbeat. com > instant-alerts > universal-health-services-nyseuhs-downgraded-to-hold-rating-by-wall-street-zen-2026-05-02

Universal Health Services (NYSE: UHS) Downgraded to Hold Rating by Wall Street Zen

3+ hour, 35+ min ago  (105+ words) Universal Health Services (NYSE: UHS - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday. Get Our Latest Stock Analysis on UHS Here are…...

Google News
marketbeat. com > instant-alerts > dexcom-nasdaqdxcm-price-target-cut-to-7500-by-analysts-at-td-cowen-2026-05-01

Dex Com (NASDAQ: DXCM) Price Target Cut to $75. 00 by Analysts at TD Cowen

13+ hour, 44+ min ago  (129+ words) Dex Com (NASDAQ: DXCM - Get Free Report) had its price objective lowered by TD Cowen from $84. 00 to $75. 00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the medical device company's stock. TD…...

Market Beat
marketbeat. com > instant-alerts > merit-medical-systems-nasdaqmmsi-given-new-8500-price-target-at-canaccord-genuity-group-2026-05-01

Merit Medical Systems (NASDAQ: MMSI) Given New $85. 00 Price Target at Canaccord Genuity Group

10+ hour, 51+ min ago  (78+ words) Check Out Our Latest Analysis on MMSI Here are the key news stories impacting Merit Medical Systems this week: Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology…...

Google News
marketbeat. com > instant-alerts > tenet-healthcare-nysethc-given-new-25200-price-target-at-guggenheim-2026-05-01

Tenet Healthcare (NYSE: THC) Given New $252. 00 Price Target at Guggenheim

17+ hour, 39+ min ago  (130+ words) Tenet Healthcare (NYSE: THC - Get Free Report) had its price objective reduced by stock analysts at Guggenheim from $283. 00 to $252. 00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a "buy" rating on…...

Market Beat
marketbeat. com > instant-alerts > orthopediatrics-nasdaqkids-announces-quarterly-earnings-results-2026-04-30

Ortho Pediatrics (NASDAQ: KIDS) Announces Quarterly Earnings Results

1+ day, 5+ hour ago  (83+ words) Here are the key takeaways from Ortho Pediatrics' conference call: Check Out Our Latest Analysis on KIDS The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and…...

Market Beat
marketbeat. com > instant-alerts > novo-nordisk-as-nysenvo-sees-significant-decrease-in-short-interest-2026-05-01

Novo Nordisk A/S (NYSE: NVO) Sees Significant Decrease in Short Interest

10+ hour, 51+ min ago  (133+ words) Here are the key news stories impacting Novo Nordisk A/S this week: The business also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were issued a dividend of $1. 2751 per share. This…...

Market Beat
marketbeat. com > instant-alerts > prestige-consumer-healthcare-inc-nysepbh-short-interest-update-2026-05-01

Prestige Consumer Healthcare Inc. (NYSE: PBH) Short Interest Update

10+ hour, 49+ min ago  (138+ words) Check Out Our Latest Stock Report on Prestige Consumer Healthcare Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies…...

Market Beat
marketbeat. com > instant-alerts > sagimet-biosciences-targets-acne-plans-us-phase-iii-for-denifanstat-after-175m-raise-2026-04-30

Sagimet Biosciences Targets Acne, Plans U. S. Phase III for Denifanstat After $175 M Raise

1+ day, 5+ hour ago  (674+ words) Sagimet Biosciences NASDAQ: SGMT said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid synthase (FASN) inhibitor, denifanstat, into a U. S. phase III registrational study…...

Market Beat
marketbeat. com > instant-alerts > tenet-healthcare-nysethc-price-target-cut-to-23600-by-analysts-at-royal-bank-of-canada-2026-05-01

Tenet Healthcare (NYSE: THC) Price Target Cut to $236. 00 by Analysts at Royal Bank Of Canada

14+ hour, 51+ min ago  (129+ words) Tenet Healthcare (NYSE: THC - Get Free Report) had its target price cut by Royal Bank Of Canada from $277. 00 to $236. 00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Royal…...